Medical technology startup Science Corporation has raised $400 million in a Series D funding round, the company said. A person familiar with the deal said investors valued the company at $3.5 billion.
Backers included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. Max Hodak, the former president of Neuralink, co-founded Science Corporation in 2021 to use new technologies to understand and interact with the brain. Hodak joined a neuroscience research lab as a college student and has pursued biotechnology ever since.
Vision device and US plans
The company's first product, PRIMA, is a device with wearable and implantable components built around a chip. It can help people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, and is also being studied for other conditions.
At TechCrunch Disrupt, Hodak announced that PRIMA is now being tested in patients with Stargardt's disease, another condition that causes blindness.
With the new funding, the company aims to bring the device to the United States through the US Food and Drug Administration's (FDA) Humanitarian Device Exemption pathway. The pathway allows experimental medical devices to be used to treat rare conditions. Science Corporation has convinced the FDA that advanced macular degeneration in both eyes is sufficiently uncommon for the company to seek authorization to use the device in the United States through that route.
A direct link to the brain
The company's longer-term ambition, however, is to connect directly to the human brain. It is developing a bio-hybrid sensor made from cultured neurons and silicon for that purpose.
Science Corporation is designing initial human trials of the device with Murat Günel, a professor of neurosurgery at Yale University. Günel told TechCrunch that the technology could offer potential treatments for Parkinson's disease, among other brain injuries and illnesses.



